Northwest Biotherapeutics, Inc. (NWBO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 2 |
| Operating profit | $m | -60 | -50 | ||||||
| Net profit | $m | -530 | 179 | -105 | -63 | -84 | -61 | -38 | -73 |
| EPS reported | $ | -0.04 | -0.03 | ||||||
| Operating cashflow per share | $ | -0.03 | -0.03 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.03 | -0.03 | ||||||
| Free cash flow | $m | -46 | -48 | ||||||
| Net debt | $m | 57 | 51 | ||||||
| Book value equity | $m | -48 | -35 | ||||||
| Book value per share | $ | -0.03 | -0.02 | ||||||
| Number of shares | m | 1,456.66 | 1,642.44 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -6.97 | -9.53 | ||||||
| P/S LTM | x | 240.49 | 152.50 | ||||||
| P/FCF LTM | x | -7.16 | -6.86 | ||||||
| EV/EBITDA LTM | x | -7.92 | -6.83 | ||||||
| EV/Sales LTM | x | 285.32 | 228.17 | ||||||
| Earnings Yield LTM | % | -18.55% | -16.29% | ||||||
| FCF Yield | % | -13.96% | -14.59% | ||||||
| Quality | |||||||||
| ROE | % | +129.23% | +62.41% | ||||||
| ROIC | % | -1.86% | -1.29% | ||||||
| Operating margin | % | -43.48% | -35.74% | ||||||
| Gross margin | % | -69.59% | -44.89% | ||||||
| FCF/Sales | % | -3357.5% | -3225.6% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -0.29% | +57.24% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.71 | -0.86 | ||||||
| Net Debt/EBITDA | x | -1.24 | -1.04 | ||||||
| EBIT/Net interest | x | 6.89 | -5.67 | ||||||
| Net debt/market cap | % | +18.12% | +21.37% | ||||||
| Net debt/Equity | x | -1.20 | -1.48 | ||||||
| Gross debt/equity | x | -1.36 | -1.62 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Northwest Biotherapeutics, Inc. (NWBO)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free